GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Recommendation of “Buy” from Brokerages

GeoVax Labs, Inc. (NASDAQ:GOVX) has received a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $14.20.

Separately, D. Boral Capital restated a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a research note on Thursday, February 27th.

GeoVax Labs Stock Down 4.3 %

Shares of GOVX stock opened at $1.35 on Friday. The stock’s fifty day simple moving average is $1.77 and its 200 day simple moving average is $2.25. GeoVax Labs has a one year low of $1.09 and a one year high of $11.18.

Hedge Funds Weigh In On GeoVax Labs

Several institutional investors have recently bought and sold shares of GOVX. Virtu Financial LLC acquired a new position in GeoVax Labs in the third quarter worth $97,000. Geode Capital Management LLC raised its holdings in shares of GeoVax Labs by 59.0% in the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after buying an additional 33,440 shares during the last quarter. Northern Trust Corp acquired a new position in GeoVax Labs during the 4th quarter worth about $29,000. Finally, Citadel Advisors LLC bought a new stake in GeoVax Labs during the 4th quarter worth about $104,000. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.